

<i>Examiner-Initiated Interview Summary</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;">Application No. 10/544,180</td> <td style="width: 50%; padding: 2px;">Applicant(s) MOHNEN ET AL.</td> </tr> <tr> <td style="padding: 2px;">Examiner CATHY K. WORLEY</td> <td style="padding: 2px;">Art Unit 1638</td> </tr> </table>	Application No. 10/544,180	Applicant(s) MOHNEN ET AL.	Examiner CATHY K. WORLEY	Art Unit 1638
Application No. 10/544,180	Applicant(s) MOHNEN ET AL.				
Examiner CATHY K. WORLEY	Art Unit 1638				

All Participants:

(1) CATHY K. WORLEY.

(2) Donna Ferber.

Date of Interview: 15 April 2009

Type of Interview:

☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
If Yes, provide a brief description: _____

Part I.

Rejection(s) discussed:
Written Description, Enablement, 102, and 103

Claims discussed:
1, 4-11, 13, 16, 20-23, and 26

Prior art documents discussed:
All

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
See Continuation Sheet

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Cathy K. Worley/
Primary Examiner, Art Unit 1638)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner called to indicate that claims that were amended to be limited in scope to nucleic acids encoding an enzyme comprising a polypeptide with at least 95% identity to SEQ ID NO:2; wherein the polypeptide catalyzes transfer of galacturonosyl residues to an oligomer of galacturonic acid residues would be fully enabled, described, and free of the prior art of record. If the product claims are amended to this scope, then process claims that depend from or otherwise include the same limitations will be rejoined. Claims directed to an isolated polypeptide will not be rejoined, because that is subject matter that is examined in a different art unit. The Examiner hoped to negotiate Examiner's amendments to be able to allow the case. Unfortunately, Donna Ferber informed the Examiner that the Applicant has indicated they wish to transfer the case to a different attorney, and therefore, she was not able to approve any Examiner's amendments..